BridgeBio Pharma (NASDAQ:BBIO) is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies. Its lead programs address rare and serious conditions such as transthyretin amyloidosis, achondroplasia, phenylketonuria and select oncology indications driven by genetic mutations. Among its most advanced candidates are acoramidis (formerly AG10), an oral TTR stabilizer for cardiomyopathy, and infigratinib, an FGFR inhibitor for cholangiocarcinoma and other cancers with FGFR alterations.
Since inception, BridgeBio has expanded its clinical and research activities across North America, Europe and Asia, collaborating with regulatory agencies and academic centers to advance its programs worldwide. The company maintains research hubs in major biotech clusters and leverages strategic partnerships to support global trials and regulatory submissions, reinforcing its commitment to addressing unmet medical needs on a multinational scale.
Neil Kumar serves as President and Chief Executive Officer, bringing extensive experience in biotech entrepreneurship and drug development. BridgeBio’s leadership team combines expertise in translational science, regulatory affairs and commercial strategy, supported by a network of investors and collaborators. This multidisciplinary approach underpins the company’s mission to translate genetic insights into safe and effective therapies for patients facing rare and life-threatening diseases.
